A theoretical radiobiological rationale supports the use of hypofractionated radiotherapy (higher radiation doses per fraction over a shorter period of time compared with conventional fractionation) for the treatment of prostate cancer. The investigators of two recently published phase III clinical trials with different designs have come to opposing conclusions regarding whether hypofractionated radiotherapy should be considered a new standard of care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dearnaley, D. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(16)30102-4 (2016).
Incrocci, L. et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(16)30070-5 (2016).
Catton, C. N. et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. J. Clin. Oncol. 34 (Suppl.), abstr. 5003 (2016).
Lee, W. R. et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J. Clin. Oncol. 34, 2325–2332 (2016).
Aluwini, S. et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 17, 464–474 (2016).
Pollack, A. et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J. Clin. Oncol. 31, 3860–3868 (2013).
Lukka, H. et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol. 23, 6132–6138 (2005).
Yeoh, E. E. et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 66, 1072–1083 (2006).
Arcangeli, G. et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78, 11–18 (2010).
Hoffman, K. E. et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 88, 1074–1084 (2014).
Arcangeli, S. et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 1172–1178 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Pollack, A., Abramowitz, M. Moderate hypofractionated radiotherapy — not yet a standard of care. Nat Rev Clin Oncol 13, 655–656 (2016). https://doi.org/10.1038/nrclinonc.2016.147
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.147
This article is cited by
-
The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study
International Journal of Clinical Oncology (2018)
